Therapy Directory

Durvalumab clinical trials

Directory of U.S. ClinicalTrials.gov public records that list Durvalumab as a study intervention. Browse Durvalumab recruiting trials, filter by phase, sponsor, or location, and open the official ClinicalTrials.gov study record for each result.

ClinicalTrials.gov public records Last synced Oct 24, 2026, 5:36 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

453

Shown on this page

Current sort

Live official records

Open in full search

Conditions: Lung Cancer, Non-small Cell Carcinoma
Interventions: Induction Durvalumab, Chemotherapy, Radiation, Consolidation durvalumab; Drug · Radiation
Lead sponsor: Rachel Sanborn; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 5
States / cities: Chicago, Illinois • Wichita, Kansas • Minneapolis, Minnesota + 2 more

Conditions: Solid Tumor
Interventions: Durvalumab; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years
Enrollment: 163 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 12
States / cities: Fullerton, California • Washington D.C., District of Columbia • Augusta, Georgia + 9 more

Conditions: Urothelial Carcinoma Recurrent, Advanced Urothelial Carcinoma
Interventions: Vactosertib(TEW-7197)/ Durvalumab; Drug
Lead sponsor: MedPacto, Inc.; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 2
States / cities: San Francisco, California • Buffalo, New York

Conditions: Urothelial Cancer
Interventions: durvalumab, Radiation Therapy; Drug · Radiation
Lead sponsor: Monika Joshi, MD; Other
Eligibility: 18 Years and older
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2022
U.S. locations: 7
States / cities: Iowa City, Iowa • Omaha, Nebraska • New Brunswick, New Jersey + 4 more

Conditions: Small-cell Lung Cancer
Interventions: Carboplatin, Cisplatin, Etoposide, Durvalumab, Stereotactic Body Radiotherapy; Drug · Radiation
Lead sponsor: Weill Medical College of Cornell University; Other
Eligibility: 18 Years and older
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 3
States / cities: Brooklyn, New York • Flushing, New York • New York, New York

Conditions: BRCA1 Gene Mutation, BRCA2 Gene Mutation, Ovarian Serous Adenocarcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma
Interventions: Durvalumab, Laboratory Biomarker Analysis, Olaparib, Tremelimumab; Biological · Other · Drug
Lead sponsor: Roswell Park Cancer Institute; Other
Eligibility: 18 Years and older · Female only
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2024
U.S. locations: 2
States / cities: Buffalo, New York • New York, New York

Conditions: Clear Cell Renal Cell Cancer, Non-Small-Cell Lung Cancer, Triple Negative Breast Neoplasms, Squamous Cell Cancer of Head and Neck, Small Cell Lung Cancer, Gastroesophageal Cancer, Melanoma, Cervical Cancer, Advanced Solid Tumours
Interventions: AZD8701, Durvalumab; Drug · Biological
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 101 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 6
States / cities: Baltimore, Maryland • St Louis, Missouri • Huntersville, North Carolina + 3 more

Conditions: Cholangiocarcinoma
Interventions: Novel combination of chemotherapy and immunotherapy; Drug
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 18 Years to 89 Years
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Soft Tissue Sarcoma
Interventions: Combination Radiation, Immunotherapy, Surgery; Combination Product
Lead sponsor: University of Maryland, Baltimore; Other
Eligibility: 18 Years and older
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2024
U.S. locations: 3
States / cities: Tucson, Arizona • Baltimore, Maryland • Pittsburgh, Pennsylvania

Conditions: Non Small Cell Lung Cancer
Interventions: Tislelizumab, Durvalumab, Ociperlimab, Chemotherapy, Radiotherapy; Drug · Radiation
Lead sponsor: BeiGene; Industry
Eligibility: 18 Years and older
Enrollment: 63 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Bolivar, Missouri

Conditions: Castration-Resistant Prostate Carcinoma, Metastatic Malignant Neoplasm in the Bone, Prostate Adenocarcinoma, Stage IV Prostate Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8, Stage IVB Prostate Cancer AJCC v8
Interventions: Durvalumab, Tremelimumab; Biological
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Metastatic Carcinoma in the Liver, Resectable Mass, Stage IV Colorectal Cancer AJCC v7, Stage IVA Colorectal Cancer AJCC v7, Stage IVB Colorectal Cancer AJCC v7
Interventions: Durvalumab, Laboratory Biomarker Analysis, Therapeutic Conventional Surgery, Tremelimumab; Biological · Other · Procedure
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2023
U.S. locations: 1
States / cities: Houston, Texas

About this Durvalumab clinical trials directory page

What this page lists: U.S. ClinicalTrials.gov public records that list Durvalumab as a study intervention, including recruiting, not yet recruiting, and active not recruiting trials.
How to narrow results: Use the filters above to scope by condition, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, age, or NCT ID within Durvalumab.
Where the data comes from: Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, ranking of trials by quality, or AI-generated medical summaries.

Durvalumab clinical trials

Filter and sort this therapy

Live official records

Durvalumab Followed by Chemoradiation and Consolidation Durvalumab for Stage III Non-small Cell Lung Cancer

Durvalumab Long-Term Safety and Efficacy Study

Vactosertib with Durvalumab in Urothelial Carcinoma Failing Checkpoint Inhibition

Durvalumab And Radiation Therapy Followed by Adjuvant Durvalumab in Patients With Urothelial Cancer (T2-4 N0-2 M0) of the Bladder

A Trial With Chemotherapy, Immunotherapy, and Radiotherapy for Patients With Newly Diagnosed Stage IV Small Cell Lung Cancer

Olaparib, Durvalumab, and Tremelimumab in Treating Patients With Recurrent or Refractory Ovarian, Fallopian Tube or Primary Peritoneal Cancer With BRCA1 or BRCA2 Mutation

First Time in Human Study of AZD8701 With or Without Durvalumab in Participants With Advanced Solid Tumours

Durvalumab and Tremelimumab With Platinum-based Chemotherapy in Intrahepatic Cholangiocarcinoma (ICC)

Neoadjuvant Durvalumab and Tremelimumab Plus Radiation for High Risk Soft-Tissue Sarcoma

A Study to Compare Ociperlimab Plus Tislelizumab Versus Durvalumab Following Concurrent Chemoradiotherapy (cCRT) in Participants With Stage III Unresectable Non-Small Cell Lung Cancer

Durvalumab and Tremelimumab in Treating Chemotherapy Naive Patients With Metastatic Castration-Resistant Prostate Cancer

Tremelimumab and Durvalumab in Treating Patients With Colorectal Cancer With Liver Metastases That Can Be Removed by Surgery

About this Durvalumab clinical trials directory page